Deepali Sachdev Selected Research

Somatomedin Receptors (Somatomedin Receptor)

1/2015	IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas.
7/2012	Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment.
4/2009	Sequencing of type I insulin-like growth factor receptor inhibition affects chemotherapy response in vitro and in vivo.
12/2008	Regulation of breast cancer metastasis by IGF signaling.
6/2007	Drug evaluation: CP-751871, a human antibody against type I insulin-like growth factor receptor for the potential treatment of cancer.
1/2007	Disrupting insulin-like growth factor signaling as a potential cancer therapy.
2/2006	Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer.
2/2004	A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Deepali Sachdev Research Topics

Disease

12	Neoplasms (Cancer) 01/2019 - 02/2004
11	Breast Neoplasms (Breast Cancer) 01/2017 - 02/2003
5	Neoplasm Metastasis (Metastasis) 01/2016 - 02/2004
2	Prostatic Neoplasms (Prostate Cancer) 06/2007 - 01/2007
1	Triple Negative Breast Neoplasms 01/2019
1	Hyperinsulinism (Hyperinsulinemia) 01/2016
1	Sarcoma (Soft Tissue Sarcoma) 01/2015

Drug/Important Bio-Agent (IBA)

9	Insulin-Like PeptidesIBA 07/2012 - 02/2003
8	Somatomedin Receptors (Somatomedin Receptor)IBA 01/2015 - 02/2004
6	Insulin-Like Growth Factor I (IGF-1)IBA 01/2007 - 02/2003
3	AntibodiesIBA 01/2019 - 02/2006
3	Insulin ReceptorIBA 01/2016 - 02/2006
2	LigandsIBA 01/2017 - 01/2007
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2015 - 03/2009
2	Biomarkers (Surrogate Marker)IBA 09/2010 - 12/2008
2	Pharmaceutical PreparationsIBA 10/2009 - 06/2007
2	Insulin (Novolin)FDA Link 01/2007 - 02/2006
2	Insulin-Like Growth Factor II (Somatomedin A)IBA 01/2007 - 01/2006
1	perlecanIBA 01/2019
1	infigratinibIBA 01/2017
1	Fibroblast Growth Factors (Fibroblast Growth Factor)IBA 01/2017
1	Cadherins (E-Cadherin)IBA 01/2016
1	Transcription Factors (Transcription Factor)IBA 01/2016
1	VimentinIBA 01/2016
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2016
1	Interleukin-13IBA 01/2015
1	AntigensIBA 01/2015
1	Chimeric Antigen ReceptorsIBA 01/2015
1	Tamoxifen FDA LinkGeneric 07/2012
1	LuciferasesIBA 10/2009
1	Biological ProductsIBA 10/2009
1	AntitoxinsIBA 10/2009
1	Immunotoxins (Immunotoxin)IBA 10/2009
1	Interleukin-4 Receptors (Interleukin 4 Receptor)IBA 10/2009
1	Epidermal Growth Factor (EGF)IBA 10/2009
1	AVE1642IBA 03/2009
1	exemestane (Aromasin)FDA Link 06/2007
1	Docetaxel (Taxotere)FDA Link 06/2007
1	Prednisone (Sone)FDA LinkGeneric 06/2007
1	Carboplatin (JM8)FDA LinkGeneric 06/2007
1	Paclitaxel (Taxol)FDA LinkGeneric 06/2007
1	Hormones (Hormone)IBA 06/2007
1	figitumumabIBA 06/2007
1	Indicators and Reagents (Reagents)IBA 01/2006
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2006
1	Peptides (Polypeptides)IBA 01/2006
1	Insulin Receptor Substrate ProteinsIBA 02/2004
1	Proteins (Proteins, Gene)FDA Link 02/2004
1	IntegrinsIBA 01/2004
1	Estrogen ReceptorsIBA 02/2003
1	Single-Chain AntibodiesIBA 02/2003

Therapy/Procedure

7	Therapeutics 01/2015 - 02/2003
1	Drug Therapy (Chemotherapy) 10/2009
1	Quantum Dots (Quantum Dot) 03/2009